Targeting cytokines in inflammatory bowel disease
MF Neurath - Science translational medicine, 2022 - science.org
Targeting cytokines in inflammatory bowel disease (IBD) is a useful clinical approach.
Potential therapies for IBD include regulatory T cell transfer to restore cytokine balance …
Potential therapies for IBD include regulatory T cell transfer to restore cytokine balance …
emerging drug therapies in inflammatory bowel disease
LB Grossberg, K Papamichael… - Alimentary …, 2022 - Wiley Online Library
Background The landscape of inflammatory bowel disease (IBD) treatment is rapidly
expanding with the development of new therapeutic options. Aim To review the mechanisms …
expanding with the development of new therapeutic options. Aim To review the mechanisms …
Microbiota-sensitive drug delivery systems based on natural polysaccharides for colon targeting
H Azehaf, Y Benzine, M Tagzirt, M Skiba, Y Karrout - Drug Discovery Today, 2023 - Elsevier
Highlights•Overview of colonic drug delivery systems.•Potential for local and systemic
delivery.•Key focus on metabolic activity of the colonic microbiota.•Challenges of microbiota …
delivery.•Key focus on metabolic activity of the colonic microbiota.•Challenges of microbiota …
[HTML][HTML] local tumor necrosis factor-α inhibition in inflammatory bowel disease
Crohn's disease (CD) and ulcerative colitis (UC) are inflammatory bowel diseases (IBD)
characterized by intestinal inflammation. Increased intestinal levels of the proinflammatory …
characterized by intestinal inflammation. Increased intestinal levels of the proinflammatory …
Ozoralizumab: first Nanobody® therapeutic for rheumatoid arthritis
Y Tanaka - Expert Opinion on Biological Therapy, 2023 - Taylor & Francis
ABSTRACT Introduction Ozoralizumab (Nanozora), a novel TNF inhibitor, was first approved
in Japan in September 2022 as a next-generation antibody for the treatment of rheumatoid …
in Japan in September 2022 as a next-generation antibody for the treatment of rheumatoid …
Landscape of new drugs and targets in inflammatory bowel disease
S Vieujean, F D'Amico, P Netter… - United European …, 2022 - Wiley Online Library
Although the therapeutic armamentarium of Inflammatory bowel diseases (IBD) physicians
has expanded rapidly in recent years, a proportion of patients remain with a suboptimal …
has expanded rapidly in recent years, a proportion of patients remain with a suboptimal …
Strategies for targeting cytokines in inflammatory bowel disease
MF Neurath - Nature Reviews Immunology, 2024 - nature.com
Cytokines produced by immune cells contribute to the development and perpetuation of
inflammatory bowel disease (IBD), namely Crohn's disease and ulcerative colitis, by …
inflammatory bowel disease (IBD), namely Crohn's disease and ulcerative colitis, by …
[HTML][HTML] NANOBODY® Molecule, a Giga Medical Tool in Nanodimensions
S Kunz, M Durandy, L Seguin, CC Feral - International Journal of …, 2023 - mdpi.com
Although antibodies remain the most widely used tool for biomedical research, antibody
technology is not flawless. Innovative alternatives, such as Nanobody® molecules, were …
technology is not flawless. Innovative alternatives, such as Nanobody® molecules, were …
[HTML][HTML] Oral delivery of biologics in inflammatory bowel disease treatment
Inflammatory bowel disease (IBD) has been posed as a great worldwide health threat.
Having an onset during early adulthood, IBD is a chronic inflammatory disease …
Having an onset during early adulthood, IBD is a chronic inflammatory disease …
Polyvalency: an emerging trend in the development of clinical antibodies
Medicine has benefited greatly from the development of monoclonal antibody (mAb)
technology. First-generation mAbs have seen significant success in the treatment of major …
technology. First-generation mAbs have seen significant success in the treatment of major …